Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

IVIG prophylaxis led to improvements in infection-free survival as well as progression free and overall survival in patients ...

Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...

Study of frail older adult patients with myeloma showed reduced disease progression and death with a regimen reducing dexamethasone exposure.

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

Tony Newberne is a high-risk myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several nonprofits ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring ...

The three-year OS rate was 74% in the belantamab mafodotin combination arm and 60% in the daratumumab combination arm. The ...

Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is ...

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...